Sinovac Biotech, Profit Margin

The latest profit margin for SVA is 0.72% as of December 2023. That compares with 43.33% in the prior-year period — down 98.3% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Sinovac Biotech,'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SVA's profit margin moved from 43.33% to 0.72% — a 98.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sinovac Biotech,'s valuation or profitability profile.

Against Healthcare companies, SVA currently prints 0.72% for profit margin, while the sector average sits near 15.58%. That is roughly 95.4% below the sector mean. Large gaps often invite a closer look at Sinovac Biotech,'s growth, margins, and balance sheet.

Profit Margin shows how effectively Sinovac Biotech, converts resources into returns. At 0.72%, SVA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 43.33% in the prior-year period — down 98.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SVA's profit margin (0.72%), review year-over-year change from 43.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.